Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
| Revision | Operations | |
|---|---|---|
| 12-19-23 by kaipe | current revision | |
| 12-19-23 by kaipe | ||
| 07-23-21 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 07-10-20 by [email protected] | ||
| 07-7-20 by [email protected] | ||
| 04-17-20 by ucsf_admin | ||
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | Dose | Notes |
|---|---|---|
|
600 mg IV q8h 450 mg PO q8h |
No renal dose adjustment | |
| Necrotizing Soft Tissue Infection & Group A Streptococcus Infection, Pelvic Inflammatory Disease | 900 mg IV Q8h | No renal dose adjustment |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
| Indication | Dose | Notes |
|---|---|---|
| Uncomplicated Infection |
600 mg IV q8h 450 mg PO q8h |
No dose adjustment in hemodialysis |
| Necrotizing Soft Tissue Infection & Group A Streptococcus Infection, Pelvic Inflammatory Disease | 900 mg IV Q8h |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.